Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia
Jithma Abeykoon, MD, Mayo Clinic, Rochester, MN, discusses adverse events associated with BTK inhibitors (BTKis) in the treatment of Waldenström’s macroglobulinemia, with reference to his study comparing bendamustine and rituximab (BR) with ibrutinib in the frontline. He mentions atrial fibrillation and bleeding abnormalities as the main factors that lead to the discontinuation of BTKis. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video Adverse events associated with BTKis in the treatment of Waldenström’s macroglobulinemia online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 29 October 2024, don't forget to share it with your friends and acquaintances, it has been viewed on our site 103 once and liked it 1 people.